NOIDA, India, Nov. 24,
2022 /PRNewswire/ -- According to a new
report published by UnivDatos Markets Insights,
the Lung Cancer Therapeutics Market is
expected to reach at USD 48 billion
in 2027, growing at a CAGR of 9% from 2021-2027. The
analysis has been segmented into disease type (non-small cell lung
cancer, small cell lung cancer); treatment (chemotherapy, radiation
therapy, immunotherapy, targeted therapy, others); molecule type
(small molecules, biologics); distribution channel (hospital
pharmacies, e-commerce, retail pharmacies, others);
Click here to view the Report Description & TOC
The Lung Cancer Therapeutics market report has been
aggregated by collecting informative data on various dynamics such
as market drivers, restraints, and opportunities. This innovative
report makes use of several analyses to get a closer outlook on the
Lung Cancer Therapeutics market. The Lung Cancer Therapeutics
market report offers a detailed analysis of the latest industry
developments and trending factors in the market that are
influencing the market growth. Furthermore, this statistical market
research repository examines and estimates the Lung Cancer
Therapeutics market at the global and regional levels.
Request for Sample Pages
The lung cancer therapeutics market is expected to
register a CAGR of around 9% over the period of 2021-2027.
Lung cancer is the second most common cancer and the leading cause
of cancer death for men and women in the
United States. The rising prevalence of lung cancer owing to
the changing lifestyles with high smoking habits which lead to a
huge pool of carcinoma lung population is one of the key factors
which is resulting in a rise in the number of people having lung
cancer. For instance, as per the American Lung Association,
smoking, the main cause of small cell and non-small cell lung
cancer contributes to 80 percent and 90 percent of lung cancer
deaths in women and men, respectively. Men who smoke are 23 times
more likely to develop lung cancer. Women are 13 times more likely
than compared to never be smokers. The rising geriatric population
with NSCLC coupled with higher adoption and wide availability of
advanced lung cancer therapeutics products in the region is
expected to drive the lung cancer therapeutics market. Furthermore,
various factors such as smoking, unhealthy diet, physical
inactivity, and advancing age, increase the risk and diagnosis of
such diseases. Therefore, the market for lung cancer therapeutics
devices is expected to witness significant growth during the
Some of the major players operating in the market include
AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company,
Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co,
Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd.,
The COVID-19 pandemic has adversely impacted the global lung
cancer therapeutics industry. Several countries enforced nationwide
lockdowns as part of measures to limit the spread of the
coronavirus. As a result, caused widespread disruption to cancer
care. In light of the pandemic, many people with cancer face
challenges, including delays in diagnosis and treatment.
The global lung cancer therapeutics market report is studied
thoroughly with several aspects that would help stakeholders in
making their decisions more curated.
- Based on treatment, the market is segmented into chemotherapy,
radiation therapy, immunotherapy, targeted therapy, and others.
Among these, the targeted therapy category accounted for the major
share of global lung cancer therapeutics. Targeted therapy is a
type of cancer treatment that targets the specific cancer cells in
the body and does not affect the functioning of normal healthy
cells which leads to the minimum adverse effects. The continuous
development of new products due to technological advancements that
would lead to the production of innovative therapies and drugs is
likely to strengthen the market of the segment during the forecast
- Based on molecule type, the market is categorized into small
molecules and biologics. Among these, small molecules are expected
to witness faster growth during the forecast period. This is mainly
due to its increasingly used in the treatment of lung cancer, owing
to the rising preference of professionals for nano-therapy.
Additionally, small-molecule drugs are small enough to enter cells
easily, so they are used for targets that are inside cells.
Have a Look at the Chapters-
Lung Cancer Therapeutics Market Geographical Segmentation
- North America (United States, Canada, and Rest of North America)
- Europe (Germany, United
Italy, France, and the Rest of Europe)
- Asia-Pacific (China, Japan,
India, Australia, and the Rest of Asia-Pacific)
- Rest of the World
North America accounted for a
major share of the lung cancer therapeutics market. The major
contributors to the growth of this market are US and Canada. This is mainly due to the increasing
incidence of cancer which causes death in countries like the U.S.
and Canada. The growing lung
cancer is more common in men than women, particularly African
American men. The chance of getting lung cancer increases with age,
and, of course, a smoking history significantly contributed to the
considerable growth of the state in the U.S. lung cancer
The major players targeting the market include
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Merck & Co
- Pfizer Inc.
- Allergan Inc.
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc
The degree of competition among prominent global companies has
been elaborated by analyzing several leading key players operating
worldwide. The specialist team of research analysts sheds light on
various traits such as global market competition, market share,
most recent industry advancements, innovative product launches,
partnerships, mergers, or acquisitions by leading companies in the
Lung Cancer Therapeutics Market. The major players have been
analyzed by using research methodologies for getting insight views
on global competition.
Key questions resolved through this analytical market
research report include:
- What are the latest trends, new patterns, and technological
advancements in the Lung Cancer Therapeutics market?
- Which factors are influencing the Lung Cancer Therapeutics
market over the forecast period?
- What are the global challenges, threats, and risks in the Lung
Cancer Therapeutics market?
- Which factors are propelling and restraining the Lung Cancer
- What are the demanding global regions of the Lung Cancer
- What will be the global market size in the upcoming years?
- What are the crucial market acquisition strategies and policies
applied by global companies?
We understand the requirement of different businesses, regions,
and countries, we offer customized reports as per your requirements
of business nature and geography. Please let us know If you have
any custom needs.
About UnivDatos Market Insights (UMI)
Browse Other Related Research Reports from UnivDatos Market
- Cancer Microbiome Sequencing Market
- Oncology Therapeutics Market
- Lung Cancer Surgery Market
- Cancer Immunotherapy Market
- U.S. Prostate Cancer Treatment Device Market
Lung Cancer Therapeutics Market Report
Accelerate at a CAGR of
North America, Europe,
APAC, Rest of World
North America to
Dominate the Global Lung Cancer
United States, Canada,
Germany, United Kingdom, Italy, France, Spain, China, Japan,
Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, F.
Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc.,
Teva Pharmaceutical Industries Ltd., AbbVie, Inc.
Market Trends, Drivers,
and Restraints; Revenue Estimation and Forecast; Segmentation
Analysis; Impact of COVID-19; Demand and Supply Side Analysis;
By Disease Type; By
Treatment, By Molecule Type; By Distribution
Channel; By Region/Country
About UnivDatos Market Insights (UMI)
UnivDatos Market Insights (UMI) is a passionate market research
firm and a subsidiary of Universal Data Solutions. We believe in
delivering insights through Market Intelligence Reports, Customized
Business Research, and Primary Research. Our research studies are
spread across topics across the world, we cover markets in over 100
countries using smart research techniques and agile methodologies.
We offer in-depth studies, detailed analysis, and customized
reports that help shape winning business strategies for our
UnivDatos Market Insights
SOURCE UnivDatos Market Insights Pvt. Ltd.